Our academic collaborators’ seminal contributions push the field forward
Our constellation of renowned thinkers and partners
The right collaborators across pharma, biotech and nonprofit
The next generation of scientific leaders in cancer immunotherapy
Stories & Announcements
PICI in the News
Resources for Press
All the Right Ingredients: A Q&A with the Founders of ArsenalBio
NanoString and Parker Institute for Cancer Immunotherapy Collaborate to Optimize Cell Therapies to Treat Cancer
Five Key Takeaways from the 2021 ASCO Annual Meeting
Develop breakthrough immune therapies to turn all cancers into curable diseases faster
The driving force behind PICI’s research and operations
Transformative science requires visionary philanthropy
Join us. Change lives.
Our research team aims to answer immunotherapy’s most fundamental questions. What happens to the immune system when a patient gets cancer? How can we make immunotherapy kill all types of tumors so more patients can live a cancer-free life? We work with the best in academia and industry to find answers, fast. And we’re building an arsenal of new tools – from cancer vaccines to next-gen cell therapies – so we can end cancer. For good.
PICI-Supported research projects
John Connolly, PhD
Chief Scientific Officer
Samantha Bucktrout, PhD
Senior Director, Research
Lisa Butterfield, PhD
Vice President, Research and Development
Theresa LaVallee, PhD
Vice President, Translational Medicine and Regulatory Affairs
Lacey Kitch, PhD
Head of Informatics
Christine (Chris) Spencer, PhD
Associate Director, Informatics
Associate Director, Biospecimen Operations
A New Model to Accelerate Therapies for One of the Deadliest Cancers
A first-of-its-kind data analysis engine for scientific discovery.
Can we outsmart cancer by learning from the past?
A data-driven approach to metastatic triple negative breast cancer
Tackling one of the toughest disease sites to unlock the promise of cell and gene therapy in solid tumors
Can we predict and prevent autoimmune disease?
Improving cancer vaccines and cell therapies for patients through AI.